Member Info for AdJshares

Mr. R. point taken. Anyone know the expected date of final results this year ? Ta much

Is that not what DD is all about? If the deal does not come off this is still a very innovative company that has a good future if it is able to strengthen. All the above noted. I bought here at 7.5p today as a top up and small average down. however, may have another go at this is the euro head manage to 5uck things over once again. AdJ

Last year's final results were on the 10th June. Can anyone remember when they were announced for this year? Slightly concerned that the Greek elections are on the 17th ! So hopefully either well before or well after. That really is going to be a bun fight. I would really like to top up here to bring my average down but am concerned that if the SP does not lift after, what will be I'm sure, good results, I am going to be left holding the baby for another set of results. Crystal ball anyone? Thanks and Regards, AdJ

However, I am looking for only one top up before I have my limit. Anyone think this will temporarily go lower or is this it? Thanks and Regards, AdJ p.s. can now buy for 7.60p

7.58p paid. drawing further away?

You beat me to it !! hope you are well and not getting slaughtered like some of us (on the markets I mean)

I bought into this share @ 13.5p FFS! Anyone know what is going on? Funding? Placement in the pipeline?

Sorry, that table did not copy well. Below are the important bits ! Adjusted operating profit* 2011 - 461,000 2010 - 170,000 = +171%! Adjusted profit after tax* 2011 - £610,000 2010 - 267,000 = +128% ! Impressive stuff.

2011 2010 % change £'000 £'000 Revenue 15,192 13,487 +13% Gross profit 6,751 5,821 +16% (Loss)/profit after tax (2,795) 93 - Adjusted operating profit* 461 170 +171% Adjusted profit after tax* 610 267 +128% Adjusted EBITDA* 1,860 1,256 +48%

Post-period event * Access to FocalPoint is the determining factor in winning the University Hospital of North Staffordshire NHS Trust's liquid based cytology contract; this is the first Trust to switch liquid based cytology technology and is worth £0.3 million per annum Laurie Turnbull, Chairman of Source BioScience, said: "2011 was another year of improvements to the business and strategic progression for Source BioScience. Revenue and operating profit, before the impact of non-recurring items, have increased again and the Group is in a strong financial position. "Key achievements have been the launch of the Overnight Service and GenomeCube which give us a dominant position as a world class provider of sequencing services and genomic products. In addition, our Healthcare division has the potential for significant growth with the approval of BD FocalPoint™ in the cervical cancer screening programme. "Significant opportunities are apparent across all areas of the Group in line with the increasing demands of the healthcare and life sciences markets for faster, more efficient and more accurate molecular diagnostics and gene sequencing services."

The Board of Source BioScience plc (LSE: SBS), the international diagnostic and genetic analysis business announces its unaudited preliminary results for the year ended 31 December 2011. Financial highlights * Revenue increased by 13% to £15.2 million (2010: £13.5 million) * Adjusted operating profit* of £0.5 million (2010: £0.2 million) * Adjusted EBITDA* increased by 48% to £1.9 million (2010: £1.3 million) * Adjusted profit after tax* of £0.6 million (2010: £0.3 million) * Loss after tax of £2.8 million (2010: profit £0.1 million) * Cash generated from operating activities of £0.6 million (2010: £0.9 million) * Cash balance at 31 December 2011 of £1.1 million (2010: £4.2 million) * Purchase of the freehold land and buildings of the Head Office premises in Nottingham, eliminating the 17 year lease obligation and increasing EBITDA by £0.5 million per annum from 2012 * Integration and associated restructuring of the imaGenes business was completed as planned; expected to deliver annualised cost savings in the region of £0.7 million *Results are stated after eliminating non-recurring restructuring costs of £0.6 million associated with the planned integration of the acquired imaGenes business and the impact of a charge of £2.8 million to reflect the fair value of the Head Office premises purchased during the year, as previously announced. Operational highlights * Major developments in LifeSciences business driving growth: * Overnight Service for DNA sequencing launched in the UK and Germany, providing the fastest available turnaround times to the life sciences research community * The world's largest integrated clone and antibody library is now available via GenomeCube, our proprietary search engine and bioinformatics tool; positive feedback from customers and demand growing * In the Healthcare business, contracts worth over £0.5 million per annum already signed with NHS Trusts following approval of the FocalPoint automated imaging platform for cervical cancer screening; further interest from other NHS Trusts expected

So that's 3.66 mln shares bought today to no sells. Whiff of a contract per chance? Come on everyone! back to this board.

I've logged in several times this morning to see if anyone has responded on the qualification for divi? If a shareholder was to sell on announcement, would they track you down and give yoy the cash. Will you have to apply with shares certificate to company. Will shareholders have to have held shares for a set period prior to announcement? Mr.R. ? Thanks and Regards, AdJ

I realised that I did not thank you for those links on Bugoil. Much appreciated (so, not Basil at all then). This was strengthening around 18-19p a while ago. Anyone got any ideas about why the SP is downward with the EU (and others) approvals around the corner. Thanks and Regards, AdJ

I am enjoying your discussion. Can either of you provide me with a link to further understand bugoil. Which oils are involved, production process etc. I know Basil and not much more. Thanks in advance, AdJ

I know chap, it was toungue in cheek. I was as surprised as others to see this dip but it seems to have come back this morning. A nice fat NHS contract first thing Monday morning would start the week very nicely, eh! Good luck to you. Regards, AdJ

Anyone have any idea who these people were buying on behalf of or anyone know anything about the company? Please share. Thanks and Regards, AdJ

Think this has alot of legs come June / July. Need to understand more. I'm heavily into BMR. Waiting for KLG to blow. TPET also seem to he a good long term bet. Anyway, SNRP should be a huge share in 6 months. All the best, AdJ

...........I see RNS's

What are the most realistic funding options here? Loans on the back of imminent monthly offtake or is the dreaded "P" word being considered? Redmane. Last year I occasionally checked into REM to see how badly that share was doing. it seemed you spent most of your day every day knocking everything flat. I hope. you are here with your SNRP hat on? because i could not stand more of that type of posting. Regards, AdJ